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Manuscript received September 2, 2017 and accepted October 30, 2017AbstractIn view of decreasing lead exposure and guidelines endorsing ambulatory above office blood pressure (BP) measurement, we
reassessed association of BP with blood lead (BL) in 236 newly employed men (mean age, 28.6 years) without previous lead
exposure not treated for hypertension. Office BP was the mean of five auscultatory readings at one visit. Twenty-four-hour BP
was recorded at 15- and 30-minute intervals during wakefulness and sleep. BL was determined by inductively coupled plasma
mass spectrometry. Systolic/diastolic office BP averaged 120.0/80.7 mm Hg, and the 24-hour, awake, and asleep BP 125.5/
73.6, 129.3/77.9, and 117.6/65.0 mm Hg, respectively. The geometric mean of blood lead was 4.5 mg/dL (interquartile range,
2.60–9.15 mg/dL). In multivariable-adjusted analyses, effect sizes associated with BL doubling were 0.79/0.87 mm Hg
(P ¼ .11/.043) for office BP and 0.29/0.25, 0.60/0.10, and 0.40/0.43 mm Hg for 24-hour, awake, and asleep BP
(P  .33). Neither office nor 24-hour ambulatory hypertension was related to BL (P  .14). A clinically relevant white
coat effect (WCE; office minus awake BP, 20/10 mm Hg) was attributable to exceeding the systolic or diastolic threshold
in 1 and 45 workers, respectively. With BL doubling, the systolic/diastolic WCE increased by 0.20/0.97 mm Hg (P ¼ .57/
.046). Accounting for the presence of a diastolic WCE, reduced the association size of office diastolic BP with BL to 0.39 mm
Hg (95% confidence interval, 0.20 to 1.33; P ¼ .15). In conclusion, a cross-sectional analysis of newly hired workers before
lead exposure identified the WCE as confounder of the association between office BP and BL and did not reveal any asso-
ciation between ambulatory BP and BL. J Am Soc Hypertens 2018;12(1):14–24.  2017 The Authors. Published by Elsevier
Inc. on behalf of American Society of Hypertension. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Whereas high-level lead exposure leads to hyperten-
sion, there is no consensus as to whether low-level lead
exposure raises blood pressure (BP) and by this mecha-
nism contributes to cardiovascular complications.1,2
Lead studies traditionally relied on office BP measure-
ment. Using this approach entails inaccuracy originating
in patients, for instance as a consequence of arousal,3 in
the BP measuring device, or in the overall application
of the technique.4 In the auscultatory approach, the
observer is the principal source of bias.4 Ambulatory
monitoring substantially refines the precision of BP mea-
surement because of the greater number of readings, the
absence of digit preference and observer bias, and the
minimization of the white coat effect (WCE).3,5 Guide-
lines in North America6,7 and Europe5,8 unanimously
recommend ambulatory monitoring as the method of
choice to record BP.
In the light of falling environmental lead exposure,9–11
agencies such as the National Toxicology Program12 and
the Environmental Protection Agency13,14 reviewed the
literature in weight-of-the-evidence analyses15 and sug-
gested that blood lead levels as low as 5 mg/dL might be
associated with adverse health effects.12–15 Along similar
lines, in 2010, the American College of Occupational and
Environmental Medicine requested that the US Occupa-
tional and Health Administration (OSHA) align itself
with the scientific evidence, referring in particular to hyper-
tension and cardiovascular disease.16 However, studies in
workers suggest that the toxic effects of lead on the cardio-
vascular system occur at much higher blood lead levels than
in the population, possibly as a consequence of the healthy
worker effect.17 Using the baseline data of the ongoing
Study for Promotion of Health in Recycling Lead
(SPHERL18; NCT02243904), we assessed the association
between BP and blood lead, using both office and ambula-
tory BP measurement, in newly hired workers before occu-
pational lead exposure.MethodsStudy ParticipantsSPHERL complies with the Helsinki declaration for in-
vestigations in human subjects.19 All participants provided
written informed consent. The Ethics Committee of the
University Hospitals Leuven (Belgium) approved the study
protocol published elsewhere.18 In short, the nursing staff at
a lead–acid battery manufacturing and recycling plant in
the United States enrolled (2015–2017) new hires for
detailed health evaluations before blood lead elevations
associated with occupational exposure. By May 1, 2017,
336 of 490 invited men (68.6%) consented to participate.
Of those, we excluded 100 workers, who declinedambulatory BP monitoring (n ¼ 24) or who had fewer
than 7 or 3 ambulatory readings during wakefulness and
sleep (n ¼ 56), patients on antihypertensive drug treatment
(n ¼ 13) and workers with blood lead measurement not yet
available at the time of writing of this article (n ¼ 7). The
number of workers statistically analyzed, therefore,
totaled 236.Office BP MeasurementOffice BP was measured according to current guide-
lines20–22 with application of a stringent quality control
program.23,24 At the enrolment visit, nurses measured the
workers’ upper arm circumference. Standard cuffs had a
12  24 cm inflatable portion, but if upper arm girth ex-
ceeded 31 cm, larger cuffs with 15  35 cm bladders
were used. BP measurements were obtained on the
nondominant arm, unless at recruitment, the systolic or dia-
stolic BP differences between both arms were 10 mm Hg or
more. In this case, the cuffs for office and ambulatory BP
measurement were applied to the arm giving the highest
BP reading. After the workers had rested for 5 minutes in
the sitting position, nurses obtained five consecutive BP
readings to the nearest 2 mm Hg, using a standard mercury
sphygmomanometers. The five readings were averaged for
analysis. Heart rate was counted over 15 seconds. Terminal
digit preference and number preference were the criteria
applied for quality control of the office BP. Terminal digit
preference refers to the observer rounding off the BP
reading to a digit of her or his choosing, most often five
or zero.23,24 Number preference refers to the number of
identical BP readings made by an observer within
participants.24
At the enrollment visit, nurses administered standardized
questionnaires providing information on each worker’s
medical history, smoking and drinking habits, use of med-
ications, and previous occupational exposure. Body mass
index was weight in kilograms divided by squared height
in meters. The waist-to-hip ratio was waist circumference
divided by hip circumference.Ambulatory BP MonitoringThe ambulatory BP was recorded using validated25 oscil-
lometric Mobil-O-Graph 24-hour PWA monitors (I.E.M.
GmbH, Stolberg, Germany), which were programmed to
obtain readings at 15-minute intervals during waking hours
and every 30 minutes during sleep. On monitoring days, the
workers kept a diary, in which they recorded the beginning
and end of sleep. If the ambulatory recordings were longer
than 1 day, only the first 24 hours were analyzed. The same
SAS macro processed all recordings. Intra-individual
means of the BP readings over 24 hours and during the
awake and asleep periods were weighted by the time inter-
val between successive readings.26
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individuals.27 Office hypertension is an office BP of at least
140 mm Hg systolic or 90 mm Hg diastolic. The corre-
sponding thresholds for ambulatory hypertension are
130 mm Hg systolic and 80 mm Hg diastolic for the
24-hour BP and 135 mm Hg and 85 mm Hg and 120 mm
Hg and 70 mm Hg for the awake and asleep BP, respec-
tively.27 Truly normotensive people and hypertensive pa-
tients have a consistently normal or elevated BP on office
and awake ambulatory measurement.27 White coat hyper-
tension is a high office BP in the presence of a normal
awake BP. Its counterpart, masked hypertension, is charac-
terized by a normal office BP, but an elevated awake BP.27
If systolic and diastolic BP resulted in discordant cate-
gories, we used the highest BP to classify individuals. We
computed the WCE by subtracting the awake from the of-
fice BP and considered it clinically relevant if the office BP
was at least 20 mm Hg systolic or 10 mm Hg diastolic
higher than the awake BP.5Biochemical MeasurementsVenous blood samples obtained after 8 hours of fasting
were immediately spun and divided into aliquots. All
biochemical tests were performed by laboratories certified
by the Clinical Laboratory Improvement Amendments of
1988. Blood lead was determined by inductively coupled
plasma mass spectrometry at a laboratory certified for
blood lead analysis in compliance with the provisions of
the OSHA Lead Standard, 29CFR 1910.1025 (Occupa-
tional Safety and Health Administration). This laboratory
participates in the US CDC Blood Lead Proficiency Testing
Program. Before analysis, specimens were digested in nitric
acid and spiked with an iridium internal standard. The limit
of detection was 0.5 mg/dL. The deviation from known lead
standards ran along with the samples in each test run was
<10%. Measurements on serum included total and high-
density lipoprotein (HDL) cholesterol, cystatin C, and
g-glutamyltransferase (index of alcohol intake). The esti-
mated glomerular filtration rate (eGFR) was derived from
serum cystatin C, using the equation proposed by the
Chronic Kidney Disease-Epidemiology Collaboration.28Database Management and Statistical AnalysisFor database management and statistical analysis, we
used SAS software version 9.4 (Cary, NC, USA). The
Studies Coordinating Centre (Leuven, Belgium) developed
electronic case report forms as interactive PDF forms,
which the study nurses completed at the study side. XML
files exported from the PDFs were uploaded to a secured
server in Leuven. After quality control and addition of
the codes for symptoms, diseases, and concurrent medica-
tions, the XML files were directly imported into the SAS
database, using the SAS XML Mapper, version 9.4.Departure from normality was evaluated by Shapiro-
Wilk’s statistic. Skewness and kurtosis were computed as
the third and fourth moments about the mean divided by
the cube of the standard deviation (SD). To approximate
the normal distribution, blood lead and g-glutamyltransfer-
ase were logarithmically transformed. We reported the cen-
tral tendency and spread of continuously distributed
variables as mean and SD or as geometric mean and inter-
quartile range (IQR) for logarithmically transformed vari-
ables. In exploratory analyses, we assessed the
characteristics and the BP of workers across fourths of
the blood lead distribution. Next, we applied
multivariable-adjusted linear and logistic regression to
relate BP indexes as continuous or categorical outcomes
with the blood lead concentration while adjusting for phys-
iologically relevant covariables: first, for age and body
mass index, and in a second step, additionally for heart
rate, waist-to-hip ratio, current smoking, g-glutamyltrans-
ferase, total-to-HDL cholesterol ratio, and eGFR. Signifi-
cance was a two-tailed a-level of .05.ResultsCharacteristics of ParticipantsThe 236 workers included 108 Hispanics (45.8%), 113
Whites (47.9%), and 15 (6.3%) of Black (n ¼ 7), Asian
(n¼ 1), or mixed (n¼ 7) descent. The prevalence of smoking
and self-reported alcohol intake was 28.4% (n ¼ 67) and
47.0% (n¼ 111), respectively. Among all men, mean values
(SD) were 28.6  9.4 years (5th–95th percentile interval,
19.3–48.7 years) for age, 28.2 5.5 kg/m2 for body mass in-
dex, 4.39  0.89 mmol/L and 1.20  0.30 mmol/L for total
and HDL cholesterol, and 129.9  13.6 mL/min/1.73 m2
for eGFR. None of the workers had a history of cardiovascu-
lar disease and 2 (0.9%) had diabetes mellitus.
The blood lead concentration ranged from 0.60 to
32.0 mg/dL (Figure 1). The geometric mean blood lead
level was 4.50 mg/dL (IQR, 2.60–9.15). Ethnicity, lifestyle
habits and anthropometric characteristics, eGFR, and serum
g-glutamyltransferase did not differ (P  .28) across
fourths of the blood lead distribution (Table 1). Total
cholesterol and the total-to-HDL cholesterol ratio
decreased with increasing blood lead (Table 1). Among
23 workers (9.8%), who reported previous occupational
exposure, the geometric mean blood lead level was
3.88 mg/dL (IQR, 1.8–8.2; range, 0.9–12.3).Office BPWithin individual participants, there were no missing of-
fice BP readings in each series of five measurements. Of
2360 systolic plus diastolic BP readings, 581 (24.6%)
terminated on 0, 493 (20.9%) on 2, 381 (16.1%) on
4, 360 (15.3%) on 6, and 545 (23.1%) on 8. None of the
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Figure 1. The logarithmically transformed distribution of
blood lead. S and K are the coefficients of skewness and kurto-
sis. The P value is for departure of the actually observed dis-
tribution (dashed line) from normality (full line) according to
the Shapiro-Wilk statistic.
Table 1
Characteristics of workers by fourths of the blood lead distribution
Characteristic Blood Lead Limits, mg/dL
<2.7 2.7–4.6
No. of participants in category 61 58
No. of participants (%)
Ethnicity
Hispanic 29 (47.5) 27 (46.
Non-Hispanic White 28 (45.9) 24 (41.
Other 4 (6.6) 7 (12.1
Smokers 15 (24.6) 18 (31.
Drinking alcohol 28 (45.9) 32 (55.
Mean (SD) of characteristic
Anthropometrics
Age, y 26.9  6.6 31.0 
Body mass index, kg/m2 27.9  5.4 29.0 
Waist-to-hip ratio 0.96  0.08 0.98 
Heart rate, bpm 72.4  9.9 74.9 
Biochemical data
Total cholesterol, mmol/L 4.47  0.80 4.54 
HDL cholesterol, mmol/L 1.18  0.27 1.17 
Total/HDL cholesterol ratio 3.96  1.13 4.1 
eGFR, mL/min/1.73 m2 132.0  11.5 127.9 
g-GT, units/L 22 (16–30) 24 (17–
g-GT, g-glutamyltransferase measured as index of alcohol intake; eGF
the Chronic Kidney Disease Epidemiology Collaboration equation; HD
For g-glutamyltransferase, values are geometric mean (interquartile
P values are for linear trend.
Significance of the difference with the adjacent lower fourth: *P  .
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tive BP readings obtained in individual workers were iden-
tical in only one (0.42%) for systolic pressure and in none
for diastolic pressure. In all participants, office BP averaged
120.0  9.6 mm Hg systolic and 80.7  8.2 mm Hg dia-
stolic. The corresponding systolic and diastolic levels in
113 Whites, 108 Hispanics, and 15 workers of other ethnic-
ities were 121.1  9.2 and 81.3  7.9 mm Hg, 118.8  9.9
and 79.9  8.4 mm Hg, and 120.0  9.9 and
81.4  9.6 mm Hg, respectively, with no significant differ-
ences between ethnicities (P  .21). In exploratory ana-
lyses, office systolic and diastolic pressure did not show
any trend (P  .15) across the fourths of the blood lead con-
centration (Table 2). In regression analysis (Table 3), office
systolic and diastolic pressure tended to increase with blood
lead. These associations were consistent in unadjusted and
adjusted analyses and were not dependent on the degree of
adjustment. The effect sizes for a doubling of blood lead
were around 0.8 mm Hg systolic and 0.9 mm Hg diastolic
but reached significance (P  .045) for diastolic pressure
only. After exclusion of 47 workers with a blood lead con-
centration 10 mg/dL, the association size with diastolic
pressure remained similar but lost significance (0.85 mm
Hg; 95% confidence interval, 0.25 to 1.96, P ¼ .13).P
4.6–9.2 9.2
58 59
5) 22 (37.9) 30 (50.8) .97
4) 36 (62.1)* 25 (42.4)* .73
) 0 (0) 4 (6.8) .43
0) 19 (32.8) 15 (25.4) .86
2) 27 (46.6) 24 (40.7) .41
10.4 28.2  9.7 28.3  10.3 .75
6.3 28.5  5.0 27.5  5.3 .60
0.09 0.97  0.08 0.97  0.08 .63
12.7 73.8  10.4 73.2  12.5 .83
0.94 4.44  0.97 4.12  0.79 .027
0.28 1.18  0.30 1.29  0.35 .060
1.21 3.97  1.34 3.39  1.06 .0084
14.5 128.8  13.6 130.9  14.7 .73
31) 21 (14–27) 20 (13–29) .30
R, glomerular filtration rate estimated from serum cystatin C using
L, high-density lipoprotein; SD, standard deviation.
range).
05.
Table 2
Blood pressure by fourths of the blood lead distribution
Blood Pressure Index Blood Lead Limits, mg/dL P
<2.7 2.7–4.6 4.6–9.2 9.2
No. of participants in category 61 58 58 59
Office pressure, mm Hg
Systolic 117.9  8.9 120.0  10.7 122.4  9.9 119.7  8.5 .15
Diastolic 78.6  7.8 81.0  10.1 81.9  7 81.3  7.6 .56
Ambulatory pressure, mm Hg
24-h systolic 125.0  9.6 125.3  11.8 126.1  10.9 125.5  10.2 .71
24-h diastolic 73.5  7.0 73.5  7.9 74.5  8.8 73.1  8.0 .97
Awake systolic 128.6  10.4 128.6  12.5 130.8  12.0 129.4  11.3 .48
Awake diastolic 77.6  7.4 77.3  8.7 79.4  8.9 77.2  8.6 .85
Asleep systolic 117.5  11.5 118.8  14.7 117.4  12.1 116.8  12.5 .63
Asleep diastolic 64.9  8.4 65.7  9.3 65.1  10.7 64.5  9.8 .77
White coat effect, mm Hg
Systolic, mm Hg 10.7  9.9 8.6  10.4 8.4  11.4 9.7  11.6 .59
Diastolic, mm Hg 1.0  7.1 3.7  8.9 2.4  8.9 4.1  8.7 .094
Prevalence, % 7 (11.5) 10 (17.2) 14 (24.1) 14 (23.7) .056
No. with hypertension (%)
Office 7 (11.5) 12 (20.7) 8 (13.8) 7 (11.9) .79
24-h 17 (27.9) 18 (31.0) 26 (44.8) 20 (33.9) .25
Awake 17 (27.9) 19 (32.8) 23 (40.0) 24 (40.7) .10
Asleep 26 (42.6) 28 (48.3) 26 (44.8) 22 (37.3) .51
Cross-classification
True normotension 42 (68.9) 37 (63.8) 33 (56.9) 34 (57.6) .15
White coat hypertension 2 (3.3) 2 (3.4) 2 (3.4) 1 (1.7) .63
Masked hypertension 12 (19.7) 9 (15.5) 17 (29.3) 18 (30.5) .064
Sustained hypertension 5 (8.2) 10 (17.2) 6 (10.3) 6 (10.2) .98
Blood pressure thresholds are 140/90 mm Hg for office hypertension and 130/80 mm Hg, 135/85 mm Hg, or 120/70 mm
Hg for ambulatory hypertension over 24 h or during wakefulness or sleep. Prevalence of the white coat effect refers to an awake minus
office blood pressure difference of 20 mm Hg systolic or 10 mm Hg diastolic. True normotensive and sustained hypertensive workers
have a consistently normal or elevated blood pressure on office and ambulatory measurement during wakefulness. White coat hypertension
is a high office blood pressure with normal awake ambulatory blood pressure. Masked hypertension is a normal office blood pressure com-
bined with an elevated awake ambulatory blood pressure.
P values are for linear trend. None of the differences between adjacent columns reached significance.
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(n ¼ 34) because of the systolic threshold in 3 (1.3%) par-
ticipants, the diastolic threshold in 22 (9.3%), or both
thresholds in 9 (3.8%). In unadjusted and adjusted analyses
(Table 4), the risk of office hypertension was unrelated to
the blood lead concentration (P  .51).Ambulatory BPThe number of BP readings obtained by ambulatory moni-
toring ranged from 12 to 80 (median, 34; 5th–95th percentile
interval, 17–51) over 24 hours, from 7 to 60 (median, 20; 5th–
95th percentile interval, 9–39) during wakefulness and from
3 to 35 (median, 10; 5th–95th percentile interval, 3–24) dur-
ing sleep. In all workers, the 24-hour BP averaged
125.5  10.6 mm Hg systolic and 73.6  7.9 mm Hg dia-
stolic. The corresponding averages were 129.3  11.5 mm
Hg and 77.9  8.4 mm Hg for BP during wakefulness and
117.6  12.8 mm Hg and 65.0  9.5 mm Hg for BP duringsleep. The ambulatory BP levels did not differ between eth-
nicities (P  .089). Exploratory analyses did not reveal any
trend (P  .33) in 24-hour, awake, or asleep ambulatory BP
across fourths of the blood lead distribution (Table 2). Simi-
larly, irrespective of adjustment (Table 3 and Figure 2), the
24-hour, awake, and asleep BPs were not related to the blood
lead concentration (P .31). In unadjusted and adjusted an-
alyses (Table 4), the risk of having ambulatory hypertension
over the whole day or during sleep was not associated with
blood lead (P  .14). However, having hypertension during
wakefulness tended to increase with higher blood lead in un-
adjusted (P ¼ .11) and adjusted (P  .069) models with an
odds ratio for a doubling of blood lead of approximately 1.25.Cross-Classification of Office and Ambulatory BPIn all participants, the WCE averaged 9.4  10.8 mm
Hg systolic (P < .0001) and 2.8  8.5 mm Hg diastolic
(P < .0001). There were no disparities in the systolic and
Table 3
Association of blood pressure with blood lead
Blood Pressure Unadjusted Model Adjusted Model Fully Adjusted Model
Estimate (95% CI) P Estimate (95% CI) P Estimate (95% CI) P
Office
Systolic 0.82 (0.23 to 1.87) .12 0.78 (0.19 to 1.74) .11 0.79 (0.17 to 1.76) .11
Diastolic 0.92 (0.02 to 1.82) .045 0.90 (0.06 to 1.74) .036 0.87 (0.03 to 1.72) .043
Ambulatory
24-h systolic 0.15 (1.01 to 1.32) .80 0.24 (0.85 to 1.34) .66 0.29 (0.82 to 1.41) .60
24-h diastolic 0.20 (1.07 to 0.66) .64 0.26 (0.97 to 0.46) .48 0.25 (0.97 to 0.48) .50
Awake systolic 0.48 (0.78 to 1.75) .45 0.60 (0.59 to 1.79) .32 0.60 (0.61 to 1.81) .33
Awake diastolic 0.05 (0.98 to 0.87) .91 0.08 (0.86 to 0.71) .84 0.10 (0.90 to 0.70) .81
Asleep systolic 0.57 (1.96 to 0.82) .42 0.51 (1.86 to 0.84) .46 0.40 (1.77 to 0.97) .57
Asleep diastolic 0.37 (1.41 to 0.67) .49 0.47 (1.38 to 0.45) .31 0.43 (1.35 to 0.50) .37
White coat effect
Systolic 0.34 (0.85 to 1.53) .57 0.18 (0.97 to 1.33) .76 0.20 (0.96 to 1.35) .57
Diastolic 0.97 (0.05 to 1.90) .039 0.98 (0.06 to 1.90) .037 0.97 (0.05 to 1.90) .046
CI, confidence interval.
Partially adjusted models account for age and body mass index and fully adjusted models include as additional covariables heart rate, hip-
to-waist circumference ratio, smoking, total-to-high-density lipoprotein cholesterol ratio, g-glutamyltransferase, and estimated glomerular
filtration rate. Estimates express the difference in blood pressure in mm Hg associated with a doubling of the blood lead concentration.
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2.1  7.5 mm Hg), Hispanics (9.0  10.7 and
3.4  9.7 mm Hg), or other ethnicities (9.4  12.5 and
3.3  6.1 mm Hg).
Overall, the prevalence of a clinically meaningful WCE
of at least 20 mm Hg systolic or 10 mm Hg diastolic was
45 (19.1%), which was due to reaching the diastolic
threshold in 44 and both the systolic (20 mmHg) and dia-
stolic (10 mm Hg) thresholds in 1. In unadjusted
(P ¼ .039) and adjusted (P  .043) analyses, the odds of
having a clinically relevant WCE increased by approxi-
mately 30% for a doubling of the blood lead concentration.
Accounting for the presence of a diastolic WCE as categor-
ical variable (0, 1) removed the significance of the associ-
ation of office diastolic BP with blood lead (Figure 3). InTable 4
Risk of hypertension in relation to blood lead
Hypertension Unadjusted Model Adju
Estimate (95% CI) P Estim
Office hypertension 0.96 (0.70–1.31) .79 0.89
24-h hypertension 1.17 (0.92–1.48) .19 1.20
Awake hypertension 1.21 (0.96–1.53) .11 1.27
Asleep hypertension 0.90 (0.72–1.12) .35 0.89
White coat effect 1.37 (1.02–1.83) .039 1.36
CI, confidence interval.
Blood pressure thresholds are 140/90 mm Hg for office hypertens
Hg for ambulatory hypertension over 24 h or during wakefulness or sl
pressure difference of 20 mm Hg systolic or 10 mm Hg diastolic.
and fully adjusted models include as additional covariables heart rate, h
poprotein cholesterol ratio, g-glutamyltransferase, and estimated glome
with a doubling of the blood lead concentration.fully adjusted models, the effect size of the association of
office diastolic BP with blood lead was 0.39 mm Hg
(95% confidence interval, 0.20 to 1.33; P ¼ .15).
Discussion
The current OSHA lead standard was adopted in the late
1970s at a time when the geometric mean blood lead con-
centration in the US population was 12.8 mg/dL.16 Howev-
er, in successive rounds of the National Health Examination
Survey (NHANES), mean blood lead levels among US
adults decreased from 13.1 mg/dL in NHANES II (1976–
1980)9,10 to 1.64 mg/dL in NHANES IV (1999–2002).11
Another issue that warrants reassessment of the association
between BP and blood lead is the introduction of 24-hoursted Model Fully Adjusted Model
ate (95% CI) P Estimate (95% CI) P
(0.63–1.26) .51 0.89 (0.62–1.28) .52
(0.93–1.55) .15 1.21 (0.94–1.57) .14
(0.98–1.63) .069 1.26 (0.98–1.64) .073
(0.71–1.12) .32 0.92 (0.73–1.16) .46
(1.01–1.82) .041 1.36 (1.01–1.82) .043
ion and 130/80 mm Hg, 135/85 mm Hg, or 120/70 mm
eep. The white coat effect refers to an awake minus office blood
Partially adjusted models account for age and body mass index
ip-to-waist circumference ratio, smoking, total-to-high-density li-
rular filtration rate. Estimates are odds ratios (95% CI) associated
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Figure 2. Plot of the association of ambulatory 24-h systolic (A and B) and diastolic (C and D) blood pressure (BP) with blood lead
unadjusted (A and C) or with multivariable adjustment (B and D). r and P indicate the single (A and C) or partial (B and D) correlation
coefficients and associated statistical significance. The regression line is depicted with 95% confidence interval.
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sure BP.5–8 In the present study, we assessed the association
of BP with blood lead in 236 newly hired workers before
occupational lead exposure, at a geometric mean lead con-
centration of 4.5 mg/dL. The key findings were (1) on office
measurement, BP tended to be higher with elevated blood
lead concentration with effect sizes for a doubling of the
exposure of around 0.8 mm Hg systolic (P  .11) and
0.9 mm Hg diastolic (P  .045); (2) the 24-hour, awake,
and asleep systolic and diastolic BPs in unadjusted and
multivariable-adjusted analyses were unrelated to the blood
lead concentration; (3) the risk of office or ambulatory hy-
pertension was not correlated with blood lead; (4) and theWCE explained the significant association of office dia-
stolic BP with blood lead.
With regard to the association of BP with lead exposure,
a meta-analysis of 58,518 subjects, recruited from the gen-
eral population in 119 surveys and from occupationally
exposed workers in 12 studies, documented for a doubling
of blood lead a 1.0 mm Hg increase in systolic BP and a
0.6 mm Hg increase in diastolic BP.1 All 131 studies with
the exception of one29 exclusively applied conventional
in-office BP measurement. Some large studies, which sup-
ported a positive relation between office BP and blood lead,
based their conclusions on a single BP reading and would
therefore grossly fail current quality criteria.30,31 In a
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Figure 3. Plot of the association of office diastolic blood pressure (BP) with blood lead unadjusted (A) or with multivariable adjustment
(C). Accounting for the presence of a clinically relevant diastolic white coat effect (office minus awake diastolic BP  10 mm Hg;
panels B and D) removed the significance of the association of office diastolic BP with blood lead. r and P indicate the single (A)
or partial (B–D) correlation coefficients and associated statistical significance. The regression line is depicted with 95% confidence in-
terval. NT, WCH, MH, and SH indicate workers with true normotension or with white coat, masked, or sustained hypertension cross-
classified based on office and awake ambulatory diastolic pressure.
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auscultatory readings obtained at the participants’ homes.
At baseline (1985–1989), it averaged 130 mm Hg systolic
and 77 mm Hg diastolic, and the geometric mean blood
lead concentration was 8.7 mg/dL. Over 5.2 years of
follow-up, blood lead dropped by 2.9 mg/dL (32%), systolic
pressure decreased by 1.5 mm Hg, diastolic pressure
increased by 1.7 mm Hg, and 47 participants became hy-
pertensive. However, changes in BP and blood lead were
unrelated and baseline blood lead did not predict incidence
of hypertension (odds ratio for doubling of baseline lead,1.2; confidence interval, 0.7–2.0). The 24-hour BP
measured in 684 participants at follow-up (1991–1994)
averaged 119 mm Hg systolic and 71 mm Hg diastolic
and was unrelated to blood lead at baseline or follow-up.29
Using as keywords ‘‘blood pressure’’ and ‘‘blood lead,’’
we conducted a PubMed search (July 21, 2017) to ascertain
whether recent studies relating BP to blood lead had adop-
ted the more accurate methodologies currently available for
BP measurement. Our search identified 108 potentially
relevant articles published since the conduct of our 2002
meta-analysis.1 We excluded 78 articles as being irrelevant
22 W.-Y. Yang et al. / Journal of the American Society of Hypertension 12(1) (2018) 14–24based on title and/or abstract and carefully checked the 30
remaining articles for the methodology of BP measurement.
All 30 articles with the exception of one32 used conven-
tional office BP readings. In the Canadian Health Measures
Survey,7 six BpTRU readings were taken in each partici-
pant (n ¼ 4550; age range, 70–79 years) with the last
five averaged to determine systolic and diastolic BP. The
BpTRU (BpTRU Medical Devices Ltd., Coquitlam, British
Columbia) is an automated and validated33 electronic
monitor. Blood lead averaged 1.64 mg/dL. Systolic BP in
the bottom 5th blood lead percentile averaged 111.9 and
122.8 mm Hg in the top 95th percentile. Multivariable-
adjusted associations of systolic and diastolic BPs with
blood lead were only significant in the 40–54 years age
range, whereas for diastolic BP, the association was driven
by men.32 As in the present study and several other
studies,2,29 there was no association between the risk of
hypertension and blood lead.32
The argumentation linking cardiovascular complica-
tions to lead exposure builds on the premise that the
rise in BP in response to exposure is the mediator.30,31
However, as reviewed elsewhere,2,34 no single study docu-
mented the full track from exposure over BP to adverse
cardiovascular outcomes. In Pirkle’s landmark study,31
elevated blood lead was associated with a higher cardio-
vascular risk score, but was actually not evaluated as pre-
dictor of cardiovascular complications. A comprehensive
meta-analysis concluded that there was sufficient evidence
to infer a causal relation of hypertension with lead expo-
sure,2 but the same experts proposed that although sug-
gestive, there is not enough solid evidence for a causal
relation of lead exposure with clinical cardiovascular out-
comes.2 Reports on adverse cardiovascular outcomes in
relation to blood lead originated from large population
studies, but were not obvious in workers.2 The explana-
tions commonly put forward for the apparent contradic-
tion between epidemiologic and occupational studies are
higher statistical power in large population studies relative
to smaller occupational cohorts and selection bias, often
referred to as the healthy worker effect.17,35 Stroke is
the complication of hypertension most closely linked to
BP.36 However, 75% of strokes occur at levels of the of-
fice BP that are within the normotensive range.36 The
Global Burden of Stroke Study 1990–2013 involved 188
countries.34 Unhealthy lifestyle, clusters of unhealthy
metabolic factors, and environmental pollutants such as
lead were the first, second, and third largest contributors
to stroke-related disability-adjusted life-years lost. Glob-
ally, in low-income combined with middle-income coun-
tries and in high-income countries, lead exposure was
estimated to contribute 6.4%, 7.8%, and 1.4% to the
stroke burden.34 However, the study consortium high-
lighted that as in many other studies they had been unable
to account for major risk factors, including atrial fibrilla-
tion, substance abuse, and predisposition to strokeassociated with other disease, for example, valvular heart
disease.34
Sympathetic arousal in response to the medical environ-
ment and the observer measuring the BP causes the WCE,
characterized by an increase in heart rate, cardiac output,
and peripheral arterial resistance.3,37 In young people
with elastic central arteries and performant baroreflexes,
such as our workers, the systolic WCE is adequately buff-
ered. The diastolic BP and its WCE predominantly reflect
acute vasoconstriction mediating an increase in peripheral
resistance.38 Indeed, association of vascular reaction to
stimuli39 and BP variability40 with lead exposure were
observed in experimental or population studies.39,40 How-
ever, in a placebo-controlled double-blind randomized clin-
ical trial, BP variability did not predict cardiovascular
complications.41
Strong points of the present study are the assessment of
BP by guideline-recommended methods and the implemen-
tation of a stringent quality control program for measure-
ment of BP and blood lead. However, the study must also
be interpreted in the light of some limitations. First, we
analyzed ambulatory BP recordings with at least seven
awake and three asleep readings. However, limiting the an-
alyses to ambulatory recordings with at least 10 awake and
five asleep readings, a criterion applied by international
consortia,42–44 eliminated only 38 workers from the anal-
ysis and did not change our results. Second, we excluded
100 participants from the current analyses because of qual-
ity of ambulatory BP measurements, antihypertensive treat-
ment, or missing blood lead measurement. However,
compared with the study population, those excluded had
similar characteristics, including blood lead (4.11 vs.
4.16 mg/dL; P ¼ .27) and office BP (120.0/80.7 vs.
120.9/80.1 mm Hg; P ¼ .42/.61). Third, over the whole
day, the median number of ambulatory readings was only
34 because participants, most of whom were engaged in
physically strenuous labor, had the option to cancel read-
ings interfering with their work. Finally, the current
cross-sectional analysis includes only baseline SPHERL
data obtained before occupational lead exposure. Workers
will be kept in follow-up and will provide a unique oppor-
tunity to correlate changes in BP and blood lead over a me-
dian of 2 years, during which blood lead levels are expected
to rise 4- to 5-fold.
In conclusion, we were unable to demonstrate any asso-
ciation between blood lead as marker of exposure and the
ambulatory BP, which is currently the guideline-
endorsed5–8 state-of-the-art method to assess BP. Moreover,
our study suggests that at least part of the association of the
conventionally measured office BP with blood lead might
be attributable to the inaccuracy of office measurement
and the WCE.3,4 The American College of Occupational
and Environmental Medicine requested that OSHA align it-
self with the recent scientific evidence on the toxic effects
of low-level lead exposure, referring in particular to
23W.-Y. Yang et al. / Journal of the American Society of Hypertension 12(1) (2018) 14–24hypertension and cardiovascular disease.16 However, there
is no conclusive proof of a causal association between a
higher risk of cardiovascular complications and blood
lead at current levels of exposure.2 While the guideline-
endorsed ambulatory approach to BP measurement is
firmly established in clinical and epidemiologic research,
the time has come for occupational medicine to embrace
this technology to characterize the first hub in the pathway,
that is, the link between blood pressure and lead exposure.Acknowledgments
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